Influenza

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA

NCT00958126 | PHASE 2 | INTERVENTIONAL

The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults

11 Sites

1313 Participants

Recruiting

18 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study Site

Huntsville,Alabama,United States,35802

Study Site

San Diego,California,United States,92108

Study Site

Melbourne,Florida,United States,32935

Study Site

Peoria,Illinois,United States,61602

Study Site

South Bend,Indiana,United States,46601

Study Site

Metairie,Louisiana,United States,70006

Study Site

Baltimore,Maryland,United States,21205

Study Site

Rockville,Maryland,United States,20850

Study Site

Austin,Texas,United States,78705

Study Site

Fort Worth,Texas,United States,76135

Study Site

Salt Lake City,Utah,United States,84124

Study Eligibility Criteria

Inclusion Criteria

* Male or female aged 18 and older, inclusive, at the time of providing informed consent.
* Females of child bearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen for the duration of the study. Females of child bearing potential must return a negative urine pregnancy test result at enrolment and prior to each study vaccination.

Exclusion Criteria

* Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, thimerosal, neomycin, polymyxin, or any components of the Study Vaccine.

Additional Studies

Additional studies can be found at ClinicalTrials.gov